OncoMatch/Clinical Trials/NCT06311981
Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients
Is NCT06311981 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for non-small cell lung cancer.
To observe the effect and toxicity of carbon ion radiotherapy on local advanced non-small cell lung cancer over 75 years old patients. Systemic therapy could be targeted therapy, chemotherapy or immunotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage IIB, IIIC
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: bevacizumab (bevacizumab)
Exception: only if squamous cell carcinoma and treated before carbon ion radiotherapy
Patient with squamous cell carcinoma was treated with bevacizumab before carbon ion radiotherapy
Cannot have received: chest radiation therapy
Chest radiation therapy or radioactive particle implantation history
Lab requirements
Blood counts
ANC ≥1.5 x 10^9/L, platelet count ≥80 x 10^9/L, hemoglobin ≥9 g/dL
Kidney function
serum creatinine ≤1.5x ULN or CrCl ≥50 ml/min, urinary protein <2+ (if ≥2+, 24h urine protein ≤1g)
Liver function
total bilirubin <1.5x ULN, AST/ALT <2x ULN
Cardiac function
no serious pulmonary hypertension, cardiovascular and cerebrovascular diseases, peripheral vascular diseases, serious chronic heart disease or other complications that may affect radiotherapy
Adequate organ function: 1). Blood function: absolute neutrophil count (ANC) ≥1.5 x 109/L, platelet count ≥80 x 109/L, hemoglobin ≥9 g/dL 2). Lung function: FEV1>25%, DLCO>25% 3). Cardiac function: no serious pulmonary hypertension, cardiovascular and cerebrovascular diseases, peripheral vascular diseases, serious chronic heart disease and other complications that may affect radiotherapy.4). Adequate liver function: total bilirubin <1.5 times the upper limit of normal value, and AST, ALT<2 times the upper limit of normal value. 5). Adequate renal function: serum creatinine ≤1.5 times the upper limit of normal or calculated creatinine clearance ≥50 ml /min, and urinary protein <2+. Patients with a baseline urinary protein level of 2+ or more should have a 24-hour urine collection and evidence of a 24-hour urinary protein level of 1g or less.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify